Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong
· Delayed Price · Currency is HKD 2.140
+0.240 (12.63%)
At close: Mar 10, 2026
Clover Biopharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -909.58 | -903.43 | -138.54 | -2,452 | -6,016 | -912.9 | Upgrade
|
| Depreciation & Amortization | 27.93 | 34.03 | 69.24 | 56.67 | 24.49 | 5.59 | Upgrade
|
| Other Amortization | 6 | 6.29 | 15.62 | 37.58 | 6.6 | 1.51 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.11 | -2 | 4.74 | 8.43 | - | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | 14.01 | 14.01 | 10.31 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.4 | -0.4 | - | -0.23 | -0.91 | - | Upgrade
|
| Stock-Based Compensation | 12.05 | 16.28 | 53.52 | 95.02 | 125.21 | - | Upgrade
|
| Other Operating Activities | 717.99 | 724.13 | 1,751 | 506.99 | 3,866 | 631.21 | Upgrade
|
| Change in Accounts Receivable | -2.15 | -16.89 | -24.11 | - | - | - | Upgrade
|
| Change in Inventory | -6.81 | -8.57 | -8.7 | -2,090 | -771.75 | -50.49 | Upgrade
|
| Change in Accounts Payable | -73.23 | -127.38 | -104.09 | 268.41 | 554.74 | 24.9 | Upgrade
|
| Change in Unearned Revenue | -18.48 | 15.54 | -2,430 | 696.69 | 2,475 | 941 | Upgrade
|
| Change in Other Net Operating Assets | -14.03 | -40.11 | 73.01 | 1,182 | -1,181 | -163.91 | Upgrade
|
| Operating Cash Flow | -246.59 | -288.49 | -727.88 | -1,691 | -917.75 | 476.93 | Upgrade
|
| Capital Expenditures | 0.06 | -1.13 | -6.95 | -77.03 | -59.25 | -113.61 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.07 | 0.07 | - | 2.2 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.3 | -0.5 | -2.22 | -28.53 | -21.06 | -0.18 | Upgrade
|
| Investment in Securities | 14.12 | 4.72 | 3.02 | 65.85 | 192.44 | -280.33 | Upgrade
|
| Investing Cash Flow | 13.95 | 3.17 | -6.16 | -37.51 | 112.12 | -394.12 | Upgrade
|
| Short-Term Debt Issued | - | 80.28 | 460.79 | 293.83 | - | - | Upgrade
|
| Total Debt Issued | 93.04 | 80.28 | 460.79 | 293.83 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | -314.61 | -444.59 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -11.15 | -28.57 | -28.77 | -14.74 | -4.47 | Upgrade
|
| Total Debt Repaid | -311.11 | -325.75 | -473.16 | -28.77 | -14.74 | -4.47 | Upgrade
|
| Net Debt Issued (Repaid) | -218.07 | -245.48 | -12.37 | 265.06 | -14.74 | -4.47 | Upgrade
|
| Issuance of Common Stock | - | 0.01 | 0.08 | 453.16 | 1,750 | - | Upgrade
|
| Other Financing Activities | 345.65 | 193.97 | -130.13 | -235.07 | -163.47 | -9.59 | Upgrade
|
| Financing Cash Flow | 127.58 | -51.5 | -142.41 | 483.14 | 3,057 | 316.85 | Upgrade
|
| Foreign Exchange Rate Adjustments | 27.23 | 2.2 | 4.9 | 85.21 | -0.36 | -32.16 | Upgrade
|
| Net Cash Flow | -77.83 | -334.62 | -871.55 | -1,160 | 2,251 | 367.49 | Upgrade
|
| Free Cash Flow | -246.53 | -289.62 | -734.83 | -1,768 | -977 | 363.31 | Upgrade
|
| Free Cash Flow Margin | -476.18% | -753.84% | -1871.94% | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -0.20 | -0.23 | -0.59 | -1.60 | -0.84 | 0.48 | Upgrade
|
| Cash Interest Paid | 1.5 | 5.62 | 16.55 | 0.24 | - | - | Upgrade
|
| Levered Free Cash Flow | 448.44 | 225.07 | -450.34 | -1,584 | -1,219 | -538.39 | Upgrade
|
| Unlevered Free Cash Flow | 449.48 | 228.67 | -438.64 | -1,580 | -1,214 | -536.53 | Upgrade
|
| Change in Working Capital | -114.71 | -177.4 | -2,494 | 56.63 | 1,077 | 751.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.